CAMBRIDGE, Mass., July 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective July 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 13,093 shares of its common stock and an aggregate of 6,546 restricted stock units (RSUs) to four new employees under Blueprint Medicines' 2020 Inducement Plan.
Read more at prnewswire.com
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
